Ingenol mebutate treatment in actinic keratosis - clinical effectiveness and potential side effects.
| Autor: | Lesiak A; Department of Dermatology, Pediatric Dermatology and Oncology, Medical University of Lodz, Lodz, Poland., Maćkowska A; Student Research Group at Department of Dermatology, Pediatric Dermatology and Oncology, Medical University of Lodz, Lodz, Poland., Bednarski IA; Department of Dermatology, Pediatric Dermatology and Oncology, Medical University of Lodz, Lodz, Poland., Kolano P; Department of General and Oncological Surgery, Tomaszow Health Centre, Tomaszow Mazowiecki, Poland., Olejniczak-Staruch I; Department of Dermatology and Venereology, Medical University of Lodz, Lodz, Poland., Woźniacka A; Department of Dermatology and Venereology, Medical University of Lodz, Lodz, Poland., Sieniawska J; Department of Dermatology and Venereology, Medical University of Lodz, Lodz, Poland., Narbutt J; Department of Dermatology, Pediatric Dermatology and Oncology, Medical University of Lodz, Lodz, Poland. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Postepy dermatologii i alergologii [Postepy Dermatol Alergol] 2019 Aug; Vol. 36 (4), pp. 468-471. Date of Electronic Publication: 2019 Aug 30. |
| DOI: | 10.5114/ada.2019.87450 |
| Abstrakt: | Introduction: Actinic keratosis is a common skin disease that occurs in response to prolonged exposure to ultraviolet radiation. This problem affects up to 60% of the population over 40 years of age. Actinic keratosis is considered to be a precancerous lesion leading to squamous cell carcinoma (SCC). The new therapeutic option for the treatment of actinic keratosis is ingenol mebutate gel (0.015%, 0.05%). Aim: Retrospective evaluation of response and potential side effects of ingenol mebutate treatment in clinical practice. Material and Methods: Eight patients with actinic keratosis lesions on the face or scalp self-applied a 0.015% gel for 3 consecutive days on the 25 cm 2 marked area. They were assessed at baseline and on day 4, 7, 14 and 57. Results: All patients on day 57 presented a complete absence of AK lesions in the area of ingenol mebutate application. No adverse events were observed. Conclusions: Our study shows that ingenol mebutate is highly efficacious field treatment for actinic keratosis. Competing Interests: The authors declare no conflict of interest. (Copyright: © 2019 Termedia Sp. z o. o.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|